1.Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001;50(RR11):1–52.
2.Hirsch, MS, Brun-Vézinet, F, D'Aquila, RT, et al.Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 2000;283:2417–2426.
3.Lot, F, Abiteboul, D. Occupational HIV infection in France. Presented at the 4th Annual International Conference on Occupational Health for Health Care Workers; September 28-October 1, 1999; Montreal, Quebec, Canada. Abstract WP-25.
4.Perdue, B, Wolde Rufael, D, Mellors, J, Quinn, T, Margolick, J. HIV-1 transmission by a needlestick injury despite rapid initiation of fourdrug postexposure prophylaxis. Presented at the 6th Annual Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL. Abstract 210.
5.Beltrami, EM, Luo, C-C, de la Torre, N, Cardo, DM. Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. Infect Control Hosp Epidemiol 2002;23:345–348.
6.Tack, PC, Bremer, JW, Harris, AA, Landay, AL, Kessler, HA, Kuritzkes, DR. Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures. JAMA 1999;281:1085–1086. Letter.
7.Mehta, CR, Patel, N. Exact logistic regression: theory and examples. Stat Med 1995;14:2143–2160.
8.Roland, ME, Martin, JN, Grant, RM, et al. Who is the source of HIV exposure in the San Francisco Post-Exposure Prevention (PEP) Project? Presented at the 7th Annual Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 197.
9.Weinstock, H, Respess, R, Heneine, W, et al.Prevalence of mutations associated with human immunodeficiency virus type 1 seroconverters in the United States, 1992-1998. J Infect Dis 2000;182:330–333.
10.Boden, D, Hurley, A, Zhang, L, et al.HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135–1141.
11.Brodine, SK, Shaffer, RA, Starkey, MJ, et al.Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999;131:502–506.
12.Leigh-Brown, AJ, Precious, HM, Whitcomb, JM, et al.Reduced susceptibility of human immunodeficiency virus type 1 (HIV 1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 2000;74:10269–10273.
13.Quinn, TC, Wawer, MJ, Sewankambo, N, et al.Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921–929.
14.Ragni, MV, Faruki, H, Kingsley, LA. Heterosexual HIV-1 transmission and viral load in hemophilic patients. J Acquir Immune Defic Syndr 1998;7:42–45.
15.Hisada, M, O'Brien, TR, Rosenberg, PS, Goedert, JJ. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. J Infect Dis 2000;181:1475–1478.
16.Pedraza, MA, del Romero, J, Roldan, F, et al.Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr 1999;21:120–125.
17.Mofenson, LM, Lambert, JS, Stiehm, ER, et al.Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999;341:385–393.
18.Garcia, PM, Kalish, LA, Pitt, J, et al.Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341:394–402.
19.Dickover, RE, Garratty, EM, Herman, SA, et al.Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599–605.
20.Eastman, PS, Shapiro, DE, Coombs, RW, et al.Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177:557–564.
21.Blanche, S, Rouzioux, C, Mandelbrot, L, Delfraissy, JF, Mayaux, MJ. Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission. Presented at the 6th Annual Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL. Abstract 267.
22.Devereux, HL, Youle, M, Johnson, MA, Loveday, C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123–F127.
23.Verhofsted, C, Van Wanzeele, F, Van Der Gucht, B, De Cabooter, N, Plum, J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999;13:2541–2546.